Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Marianne Brodmann Added: 8 months ago
CIRSE Congress 2025 - 24-month results show the Biotronik Dynetic-35 cobalt chromium balloon-expandable stent was safe and effective in iliac arteries.Prof Marianne Brodmann (Medical University of Graz, Graz, AT) joins us to discuss 24-month findings from BIONETIC-I (NCT04830228). The prospective, international, multi-center, single-arm study aimed to investigate the safety and effectiveness of… View more
Author(s): Tatsuya Nakama Added: 1 year ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB… View more
Author(s): Added: 11 months ago
New York Valves 25 - Quantitative findings from Tri-QOL showed a strong correlation between tricuspid regurgitation (TR) reduction and KCCQ improvement after transcatheter tricuspid valve intervention (TTVI).Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, Kansas City, US) discusses findings from a quantitative analysis from the Tri-QOL study which aimed to assess the optimal result… View more
Author(s): Julien Dreyfus Added: 1 year ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating… View more
Author(s): Naoki Hayakawa Added: 1 year ago
LINC 2025 - Three-year outcomes of drug-coated balloon (DCB) treatment for femoropopliteal (FP) chronic total occlusive (CTO) lesions show low patency rates in patents with multiple independent risk factors for patency loss. However, patients without risk factors achieved acceptable patency rates and clinical outcomes of freedom from clinically driven target lesion revascularization, reoclussion… View more
Author(s): Vlasis Ninios Added: 6 months ago
PCR London Valves 2025 - Dr Vlasis Ninios (Interbalkan European Medical Center, GR) discusses one-year outcomes from the AltaValve Early Feasibility Study, evaluating a novel atrial fixation system for transcatheter mitral valve replacement in patients with severe mitral regurgitation.This prospective, single-arm, multicenter study enrolled high surgical risk patients with moderate to severe or… View more